Journal Information
Vol. 13. Issue 3.
Pages 397-418 (May - June 2007)
Share
Share
Download PDF
More article options
Vol. 13. Issue 3.
Pages 397-418 (May - June 2007)
Documentos das Comissões de Trabalho / Working Committee Documents
Open Access
Tratamento da tuberculose latente: Revisão das normas, 20062
Treatment of latent tuberculosis infection: Update of guidelines, 2006
Visits
5599
Raquel Duarte1, Joana Amado1, Helena Lucas1, José Manuel Sapage1
This item has received

Under a Creative Commons license
Article information
Resumo

A Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia, sentindo a necessidade de criar normas de actuação referentes à terapêutica da tuberculose latente, coordenou a elaboração de um conjunto de recomendações, com vista a uniformizar os procedimentos nesta área. Para a elaboração do presente documento, contou com a colaboração de elementos das sociedades portuguesas de Medicina Interna, de Pediatria e de Doenças Infecciosas. Procedeu-se a uma revisão e actualização das normas para o rastreio e tratamento da tuberculose latente no adulto imunocompetente e na criança, bem como em adultos e crianças infectadas pelo vírus da imunodeficiência humana. As presentes normas devem ser entendidas como linhas gerais de orientação, e a sua aplicação não deve dispensar a análise de cada caso individual.

Rev Port Pneumol 2007; XIII (3): 397-418

Palavras-chave:
Tuberculose latente
rastreio
quimioprofilaxia
terapêutica
Abstract

The Tuberculosis Working Group of the Portuguese Society of Pulmonology, feeling the need to develop guidelines for the diagnosis and treatment of latent tuberculosis infection, compiled a set of recommendations, in view to standardize procedures on this area. This document was prepared in collaboration with the Portuguese Societies of Internal Medicine, Pediatrics and Infectious Diseases. A review and update of guidelines for tracing and treatment of latent tuberculosis infection was made, concerning immunocompetent children and adults, as well as immunocompromised children and adults due to HIV infection. It is understood that these guidelines are to be used as general recommendations, and they should not replace the individual analysis of each case.

Rev Port Pneumol 2007; XIII (3): 397-418

Key-words::
Latent tuberculosis infection
tracing
chemoprophylaxis
treatment
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
American Thoracic Society.
CDC. Targeted Tuberculin Testing and Treatment of latent Tuberculosis Infection.
Am J Resp Crit Care Med, 101 (2000), pp. S221-S247
[2.]
M.M.W.R. Update.
Fatal and Severe Liver Injuries Associated with Rifampicin and Pyrazinamide for Latent Tuberculosis Infection, and revisions in American Thoracic Society/CDC Recomendations-United States.
MMWR, 50 (2001), pp. 34
[3.]
MMWR.
Recommendations. Implementation of Target Tuberculin Testing. MMWR 2000;49,6 ERS Task Force. Tuberculosis management in Europe.
Eur Resp J, 14 (1999), pp. 978-992
[4.]
Revin Schwartzman.
Latent tuberculosis infection: old problem, new priorities.
CMAJ, 166 (2002),
BIBLIOGRAFIA
[1.]
Enfant en Milieu tropical – La tuberculose de l’enfant.
encore aujourd’hui, (1992), pp. 196-197
[2.]
A. Kochi.
The global tuberculosis situation and the new control strategy of the World Health Organization.
Tubercle, 72 (1991), pp. 1-6
[3.]
Direcção Geral da Saúde, Núcleo de Tuberculose, Dr. A Fonseca Antunes.
[4.]
K.H.K. Hsu.
Thirthy years after isoniazid.
Its impact on tuberculosis in children and adolescents. JAMA, 251 (1984), pp. 1283-1285
[5.]
Micromedex (R) Healthcare Series, Drugdex Drug Evaluation, vol. 115.
RESTANTE APOIO BIBLIOGRÁFICO
[Tuberculosis management in Europe, 1999]
Tuberculosis management in Europe.
Ers Task Force.
Eur Respir J, 14 (1999), pp. 978-992
[Tuberculosis]
Tuberculosis; Jeffrey R Stavice and Margaret H S Smith; section 16.
[Textbook of Pediatric Infectious Disease;]
Textbook of Pediatric Infectious Disease; 4ª edição, vol 1; pp. 1196-1239.
[American Thoracic Society, 2000]
American Thoracic Society.
Targeted tuberculin testing and treatment of latent tuberculosis infection.
Am J Respir Crit Care Med, 161 (2000), pp. S221-S247
[Smith, 2001]
Kim C. Smith.
Tuberculosis in children.
Curr Probl Pediatr, 31 (2001), pp. 5-30
BIBLIOGRAFIA
[1.]
A. Karen, R. Timothy, et al.
Tuberculosis and HIV.
AIDS Clinical Care, 14 (2002),
[2.]
D. Wilkinson.
Drugs for preventing tuberculosis in HIV infected persons.
Cochrane Review, (2002),
[3.]
C.F. Paredes.
HIV infection as a risk factor for activation of latent tuberculosis.
Infect Med, 19 (2002), pp. 475-479
[4.]
H.D. Gayle, et al.
Prevention and treatment of tuberculosis among patients infected with HIV: principles of therapy and revised recommendations.
Centers for disease control and prevention, 47 (1998), pp. 1-53
[5.]
J.L. Johnson, et al.
Duration of efficacy of treatment of latent tuberculosis infection in HIV infected adults.
AIDS, 15 (2001), pp. 2137-2147
[6.]
A.M.F. Pinho, et al.
Chemoprophylaxia for tuberculosis and survival of HIV-infected patients in Brazil.
AIDS, 15 (2001), pp. 2129-2135
[7.]
R.M. Jasmer, et al.
Latent tuberculosis infection.
NEJM, 347 (2002), pp. 1860-1866
[8.]
American Thoracic Society.
Targeted Tuberculin Testing and Treatment of latent tuberculosis infection.
Am J Resp Crit Care Medicine, 61 (1999), pp. 5221-5246
[9.]
Canadian Tuberculosis Standards 2000–5 th edition. Health Canada and The Lung Association.
[10.]
B Thor Soc Joint Tuberculosis Committee.
Control and prevention of tuberculosis in the United Kingdom: Code of practice.
Thorax, 55 (2000), pp. 887-901
[11.]
Com. Trabalho de Tuberculose da SPP..
Tuberculinas.
Rev Port Pneumol, 1 (1995), pp. 229-239
[12.]
Com. Trabalho de Tuberculose da SPP.
Tuberculose-infecção.
Rev Port Pneumol, 2 (1996), pp. 6-8
[13.]
CDC targeted Tuberculin testing and treatment of latent tuberculosis infection.
MMWR, (2000), pp. 49
BIBLIOGRAFIA
[1.]
Dados Estatísticos da Direcção Geral da Saúde.
Programa Nacional de Luta contra a Tuberculose (PNT).
Lisboa, Março de, (2003),
[2.]
A. Gomes, J.M. Carvalho, M.C. Gomes.
Comissão de Trabalho de Tuberculose da SPP.
Tuberculinas. Rev Port Pneumol, 1 (1995), pp. 229-239
[3.]
A. Lalvani, A.A. Pathan, et al.
Rapid Detection of Mycobacterium tuberculosis Infection by Enumeration of Antigen-specific T Cells.
Am J Respir Crit Care Med, 163 (2001), pp. 824-828
[4.]
P.F. Barnes.
Diagnosing Latent Tuberculosis Infection. The 100-year Upgrade.
Am J Respir Crit Care Med, 163 (2001), pp. 807-808
[5.]
Centers for Disease Control and Prevention.
Guidelines for Using the QuantiFERON-TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection.
MMWR, 52 (2003), pp. 15-18
[6.]
F. Neves Almeida, M.H. Seabra, et al.
Verificação da Alergia pós-vacinal por BCG.
Utilização do Mantoux a 10 UT de PR 23. J Médico, 123 (1992), pp. 360-362
[7.]
N.J. Thompson, J.L. Glassroth, et al.
The Booster Phenomenon in Serial Tuberculin Testing.
Am Rev Resp Dis, 119 (1979), pp. 587-597
[8.]
Villar M. Propostas para a Interpretação e Utilização, no Dia a Dia, da Prova Tuberculínica. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[9.]
Pereira L, Marques L, et al. Diagnóstico e Tratamento da Tuberculose em Pediatria. Recomendações das Secções de Pneumologia e Infecciologia Pediátrica da Sociedade Portuguesa de Pediatria.
[10.]
Rui Sarmento e Castro.
Tuberculose em doentes infectados pelo vírus da imunodeficiência humana.
Tese de Mestrado em Saúde Pública, (1999),
[11.]
Centers for Disease Control and Prevention.
Anergy skin testing and tuberculosis preventive therapy for HIV-infected persons: revised recommendations.
MMWR, 46 (1997), pp. 1-10
[12.]
L. Wang, M.O. Turner, et al.
A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements.
Thorax, 57 (2002), pp. 804-809
[13.]
P.G. Smith.
BCG vaccination.
Clinical Tuberculosis, pp. 299-300
[14.]
J. Ninane, A. Grymonprez, et al.
Disseminated BCG in HIV infection.
Archives of Disease in Childhood, 63 (1998), pp. 1268-1269
[15.]
S. Lallement-Le Coeur, M. Lallement, et al.
Bacillus Calmette-Guérin immunization in infants born to HIV-1 seropositive mothers.
AIDS, 5 (1991), pp. 195-199
[16.]
P. Msellati, et al.
BCG vaccination and pediatric HIV infection – Rwanda 1988-1990.
Morbid. Mortal. Weekly Rep, 40 (1991), pp. 833-836
[17.]
2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. http://www.aidsinfo.nih.gov.
[18.]
Carvalho JM. Profilaxia da Tuberculose: O BCG e a Quimioprofilaxia. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[19.]
C. Barreto, et al.
Tratamentos curtos em Tuberculose infantil.
Rev Port Pediatria, 20 (1989), pp. 239-244
[20.]
American Thoracic Society.
Centers for Disease Control and Prevention. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.
Am J Respir Crit Care Med, 161 (2001), pp. S221-S247
[21.]
D.L. Cohn.
Treatment of Latent Tuberculosis Infection: Renewed Opportunity for Tuberculosis Control.
Clin Infect Dis, 31 (2000), pp. 120-124
[22.]
H.F. Lecoeur, C. Truffot-Pernot, J.H. Grosset.
Experimental Short-course Preventive Therapy of Tuberculosis with Rifampin and Pyrazinamide.
Am Rev Resp Dis, 140 (1989), pp. 1189-1193
[23.]
J.E. Stout, J.J. Engemann, et al.
Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 824-827
[24.]
M. Narita, M. Kellman, et al.
Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection.
Chest, 122 (2002), pp. 1292-1298
[25.]
J.M. Carvalho, P. Pamplona.
Normas para a Quimioprofilaxia da Tuberculose.
Boletim da SPP, (2000), pp. 35
[26.]
Centers for Disease Control and Prevention.
Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors.
MMWR, 49 (2000), pp. 185-189
[27.]
American Thoracic Society.
Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of Tuberculosis.
Am J Respir Crit Care Med, 167 (2003), pp. 603-662
[28.]
Diniz A. Tuberculose e Infecção pelo VIH: o Tratamento. Edição em livro dos conteúdos disponibilizados em www.aidscongress.net entre 14/10/2002 e 29/11/2002, no III Congresso Virtual HIV/AIDS.
[29.]
WorKing Group on Antiretroviral therapy.
Medical Management of Infants, Children and Adolescents with HIV Infection. Antiretroviral therapy and Medical Management of Pediatric HIV Infection.
Pediatrics, 102 (1998), pp. 1005-1057
[30.]
WorKing Group on Antiretroviral therapy and Medical Managemment of HIV, Guidelines for the use of antiretroviral agents in Pediatric HIVinfection, (2001), pp. 1-67

Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia Apoio científico de: Sociedade Portuguesa de Medicina Interna, Sociedade Portuguesa de Pediatria e Sociedade Portuguesa de Doenças Infecciosas.

Coordenação.

Copyright © 2007. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?